---
title: "Cross Linked Sodium Carboxymethyl Cellulose Market, Global Outlook and Forecast 2025-2032 Professional Edition"
datePublished: Tue Sep 02 2025 02:14:23 GMT+0000 (Coordinated Universal Time)
cuid: cmf1x0iz1000202l457li1kxu
slug: cross-linked-sodium-carboxymethyl-cellulose-market-global-outlook-and-forecast-2025-2032-professional-edition

---

# Cross Linked Sodium Carboxymethyl Cellulose Market, Global Outlook and Forecast 2025-2032 Professional Edition

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>Global Cross-Linked Sodium Carboxymethyl Cellulose market size was valued at USD 312.5 million in 2023 and is projected to reach USD 482.7 million by 2030, exhibiting a CAGR of 6.4% during the forecast period. While pharmaceutical applications dominate demand, growth is further accelerated by increasing adoption in food additives and industrial applications.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/241245/global-cross-linked-sodium-carboxymethyl-cellulose-forecast-edition-market">
            https://www.24chemicalresearch.com/download-sample/241245/global-cross-linked-sodium-carboxymethyl-cellulose-forecast-edition-market</a></b></div><br><p>
</p><p>Cross-Linked Sodium Carboxymethyl Cellulose (CL-Na CMC) is a modified cellulose derivative characterized by its enhanced stability and controlled solubility. This white to off-white powder serves as a <strong>super-disintegrant</strong> in pharmaceutical formulations, particularly in tablets and capsules where rapid drug release is required. The material's unique cross-linked structure provides superior swelling properties compared to conventional Na CMC.</p><p>
</p><p>Market expansion is driven by rising pharmaceutical production, particularly in emerging economies where generic drug manufacturing is growing at 8-10% annually. Furthermore, regulatory approvals for novel drug formulations incorporating CL-Na CMC and increasing R&amp;D investments by major players like DuPont and Roquette are creating new opportunities. Recent innovations include the development of low-viscosity grades optimized for pediatric and geriatric dosage forms, addressing key challenges in patient compliance.</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Growing Pharmaceutical Applications to Accelerate Market Expansion</strong></p><p>
</p><p>The pharmaceutical industry's increasing adoption of cross-linked sodium carboxymethyl cellulose (CLCMC) as a superior excipient is driving substantial market growth. This modified cellulose derivative offers exceptional binding, disintegration, and controlled release properties, making it indispensable for tablet formulations. With over 60% of oral solid dosage forms now utilizing CLCMC-based excipients, the market is experiencing robust demand. The compound's ability to enhance drug stability and bioavailability while meeting stringent pharmacopeial standards has positioned it as a preferred choice for formulators. Recent innovations in modified-release formulations, particularly for sensitive APIs, are further propelling adoption rates across both branded and generic drug segments.</p><p>
</p><p style="text-align:center"><strong>Expansion of Generic Drug Production to Fuel Demand</strong></p><p>
</p><p>The global push for affordable healthcare has created unprecedented demand for generic medications, directly benefiting the CLCMC market. With patent expirations expected to release $251 billion worth of branded drugs to generic competition by 2030, manufacturers are increasingly relying on high-performance excipients like CLCMC to ensure product quality while maintaining cost efficiency. The material's versatility enables precise replication of branded drug dissolution profiles - a critical factor in bioequivalence testing. Regulatory support for generic drug approval pathways in emerging markets is creating additional growth avenues, with Asia-Pacific generic production volumes projected to grow at nearly 8% CAGR through 2032.</p><p>

</p><p><strong>â¤ The U.S. FDA's recent guidance on ANDA submissions specifically recommends CLCMC for modified-release formulations, recognizing its superior performance characteristics.</strong></p><p>
</p><p>Furthermore, the market is witnessing strategic vertical integration, with leading cellulose producers acquiring specialized pharmaceutical excipient manufacturers to secure supply chains and enhance product offerings. These consolidations are expected to drive technological advancements while improving production economies of scale.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Fluctuating Raw Material Costs to Challenge Market Stability</strong></p><p>
</p><p>The CLCMC market faces significant pricing pressure from volatile cellulose feedstock costs, with wood pulp prices experiencing 12-15% annual fluctuations in recent years. This volatility stems from multiple factors including supply chain disruptions, environmental regulations affecting forestry operations, and competing demand from paper and textile industries. Manufacturers must absorb these cost variations while maintaining stringent pharmacopeial specifications, creating margin compression that discourages new market entrants. The capital-intensive nature of cellulose modification facilities - requiring investments exceeding $50 million for world-scale plants - further exacerbates these financial pressures.</p><p>
</p><p style="text-align:center"><strong>Regulatory Compliance Burden to Limit Growth Potential</strong></p><p>
</p><p>Stringent and evolving global excipient regulations present persistent challenges for CLCMC producers. The implementation of IPEC-GMP standards across major markets has increased compliance costs by approximately 30% since 2020, with full traceability requirements adding significant operational complexity. Registration timelines in emerging markets now exceed 18 months in many cases, delaying market entry strategies. Furthermore, divergence in pharmacopeial monographs between USP, EP, and JP creates formulation challenges for global drug manufacturers, necessitating customized product variants that increase inventory and testing burdens.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Biopharmaceutical Formulation Breakthroughs to Create New Applications</strong></p><p>
</p><p>The emergence of CLCMC as a stabilization agent for biologic formulations represents a transformative market opportunity. Recent studies demonstrate its efficacy in protecting protein therapeutics against aggregation and degradation, with particular promise for subcutaneous delivery systems. As the biologics market expands beyond $500 billion by 2025, formulation scientists are actively evaluating CLCMC-based matrices for next-generation biosimilars and complex generics. Several major pharma companies have already filed patents covering novel CLCMC applications in monoclonal antibody stabilization, signaling strong future demand growth.</p><p>
</p><p style="text-align:center"><strong>Sustainable Sourcing Initiatives to Drive Premium Product Development</strong></p><p>
</p><p>Growing emphasis on environmentally sustainable excipients is prompting manufacturers to innovate in renewable sourcing solutions. The development of CLCMC derived from non-wood alternatives like agricultural residues and recycled textiles is gaining momentum, with pilot-scale production achieving 95% purity standards. This aligns with pharmaceutical industry commitments to reduce supply chain carbon footprints by 45% before 2030. Early adopters of green chemistry approaches are securing premium pricing advantages while meeting ESG investment criteria, creating a compelling value proposition for ethically conscious healthcare providers and payers.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Technical Limitations in High-Dose Formulations</strong></p><p>
</p><p>While CLCMC excels in standard dosage forms, technical challenges emerge in high-potency applications where drug loading exceeds 60% of tablet mass. The polymer's swelling characteristics can negatively impact compactibility and dissolution at these concentrations, requiring extensive formulation optimization. This limitation restricts adoption in certain therapeutic categories like oncology and antiviral treatments where high active ingredient loads are common. Overcoming these technical barriers requires significant R&amp;D investment, with current bioavailability enhancement solutions adding approximately 20-25% to formulation costs.</p><p>
</p><p style="text-align:center"><strong>Competitive Pressure from Alternative Excipients</strong></p><p>
</p><p>The market faces intensifying competition from next-generation synthetic polymers offering similar functionality profiles. These alternatives leverage advanced manufacturing techniques to achieve tighter particle size distributions and more consistent batch-to-batch performance. While currently priced at a 15-20% premium to CLCMC, their adoption is growing in high-value specialty formulations. Market leaders must therefore accelerate process innovation to maintain technological leadership while addressing cost competitiveness concerns through operational excellence initiatives and strategic sourcing partnerships.</p><p>
</p><p>
<strong>Segment Analysis:</strong></p><p>
<strong>By Type</strong></p><p>
</p><p><strong>Cotton Origin Dominates the Market Due to Superior Purity and Pharmaceutical-Grade Requirements</strong></p><p>
</p><p>The market is segmented based on type into:</p><p>
</p><p>Cotton Origin</p><p>Wood Origin</p><p>
<strong>By Application</strong></p><p>
</p><p><strong>Tablet Formulation Segment Leads Due to Extensive Use in Oral Solid Dosage Forms</strong></p><p>
</p><p>The market is segmented based on application into:</p><p>
</p><p>Tablet</p><p>Capsule</p><p>Granule</p><p>
<strong>By End-Use Industry</strong></p><p>
</p><p><strong>Pharmaceutical Industry Accounts for Largest Share Owing to Binder and Disintegrant Properties</strong></p><p>
</p><p>The market is segmented based on end-use industry into:</p><p>
</p><p>Pharmaceutical</p><p>Food &amp; Beverage</p><p>Personal Care &amp; Cosmetics</p><p>
</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Strategic Collaborations and Capacity Expansions Drive Market Competition</strong></p><p>
</p><p>The global Cross-Linked Sodium Carboxymethyl Cellulose (CL-NaCMC) market exhibits a <strong>moderately concentrated</strong> competitive structure, with established chemical manufacturers and specialty pharmaceutical excipient suppliers vying for market share. <strong>Roquette FrÃ¨res</strong> and <strong>DuPont Nutrition &amp; Biosciences</strong> collectively commanded approximately <strong>35-40% market share in 2024</strong>, leveraging their vertically integrated production capabilities and extensive distribution networks across North America and Europe.</p><p>
</p><p>While <strong>JRS Pharma</strong> maintains technological leadership in wood-origin CL-NaCMC formulations, <strong>Tianjin ILE Pharmaceutical Materials</strong> has emerged as the dominant Asian player through aggressive pricing strategies and rapid capacity expansions. The company increased its production capacity by <strong>22% in 2023 alone</strong> to meet growing regional demand.</p><p>
</p><p>Market consolidation accelerated in 2024 with <strong>DuPont's acquisition of Prachin Chemical's</strong> excipient division, strengthening its position in high-value pharmaceutical applications. Similarly, Roquette has invested over <strong>$50 million</strong> in R&amp;D initiatives focused on developing next-generation cross-linking technologies to enhance product performance in controlled-release formulations.</p><p>
</p><p>Mid-tier participants including <strong>DKS Co. Ltd.</strong> (Japan) and <strong>WeiMai Pharmaceutical Excipients</strong> (China) are responding through strategic collaborations with local universities and contract manufacturing organizations to improve product quality and expand their customer base.</p><p>
<strong>List of Key Cross-Linked Sodium Carboxymethyl Cellulose Manufacturers</strong></p><p>
</p><p>Roquette FrÃ¨res (France)</p><p>DuPont de Nemours, Inc. (U.S.)</p><p>JRS Pharma GmbH &amp; Co. KG (Germany)</p><p>Tianjin ILE Pharmaceutical Materials Co., Ltd. (China)</p><p>DKS Co. Ltd. (Japan)</p><p>WeiMai Pharmaceutical Excipients Co. (China)</p><p>Nippon Paper Industries Co., Ltd. (Japan)</p><p>AkzoNobel Specialty Chemicals (Netherlands)</p><p>Ashland Global Holdings Inc. (U.S.)</p><p>
</p><p>The competition landscape is witnessing a paradigm shift as European and North American manufacturers focus on high-margin specialty grades, while Asian producers capture commodity segment market share through cost leadership. This bifurcation strategy has led to <strong>diverging gross margins</strong> ranging from <strong>18-25%</strong> for bulk producers to <strong>35-42%</strong> for specialty manufacturers in 2024.</p><p>
</p><p>Emerging market participants are adopting <strong>asset-light business models</strong>, outsourcing production to toll manufacturers while investing in application development and technical service capabilities. This approach has enabled companies like <strong>Chemorse Limited</strong> (India) to rapidly scale operations without significant capital expenditures.</p><p>
</p><p>Looking ahead to 2032, competitive differentiation will increasingly hinge on <strong>regulatory compliance capabilities</strong>, as evolving pharmacopoeia standards and sustainability requirements create both challenges and opportunities across the value chain.</p><p>
</p><p>
<strong>CROSS LINKED SODIUM CARBOXYMETHYL CELLULOSE MARKET TRENDS</strong></p><p>
<strong>Pharmaceutical Industry Expansion Driving Market Growth</strong></p><p>
</p><p>The global pharmaceutical industry's increasing demand for excipients is a key driver for the cross-linked sodium carboxymethyl cellulose (CCMC) market. With over 60% of CCMC currently used in tablet formulations, the market is benefiting from rising pharmaceutical production worldwide. Recent data indicates that tablet production volumes grew by approximately 7% annually between 2020-2024, with sustained growth anticipated through 2032. The unique properties of cross-linked CCMC â including its superdisintegrant capabilities and compatibility with direct compression â make it particularly valuable for fast-dissolving oral dosage forms, which account for nearly 30% of new drug formulations.</p><p>
<strong>Other Trends</strong></p><p>
</p><p><strong>Sustainability Initiatives Shaping Raw Material Sourcing</strong></p><p>
</p><p>The market is experiencing a notable shift toward sustainable sourcing practices, with wood-origin CCMC gaining traction as manufacturers seek alternatives to traditional cotton-based products. While cotton-origin CCMC currently holds about 65% market share, wood-derived variants are projected to grow at a faster 9% CAGR through 2032. This trend aligns with broader industry moves toward sustainable excipients and responds to concerns about cotton supply chain volatility. Several major manufacturers have announced plans to increase wood-based production capacity by 2025 to meet anticipated demand from environmentally-conscious pharmaceutical customers.</p><p>
<strong>Technological Advancements in Drug Delivery Systems</strong></p><p>
</p><p>Innovation in controlled-release formulations is creating new opportunities for cross-linked CCMC applications. The material's unique swelling properties make it ideal for modified-release tablets, a segment expected to grow significantly as pharmaceutical companies develop more sophisticated delivery systems. Recent research has demonstrated improved bioavailability in poorly soluble drugs when using optimized CCMC-based matrices, leading to increased R&amp;D investment in this area. The market is also benefiting from advancements in co-processing technologies that enhance CCMC's performance characteristics while maintaining regulatory compliance.</p><p>
<strong>Regulatory Environment Impacting Market Dynamics</strong></p><p>
</p><p>Stricter pharmaceutical excipient regulations are reshaping the competitive landscape for cross-linked CCMC suppliers. The implementation of new quality standards across major markets has accelerated consolidation among manufacturers, with companies investing heavily in cGMP-compliant production facilities. Nearly 45% of industry players reported upgrading their quality systems between 2022-2024 to meet evolving regulatory expectations. This trend favors established manufacturers with robust compliance infrastructures while creating barriers for smaller regional producers, potentially leading to further market concentration through 2032.</p><p>

<strong>Regional Analysis: Cross Linked Sodium Carboxymethyl Cellulose Market</strong></p><p>

  
    North America
    
      North America dominates the global cross linked sodium carboxymethyl cellulose (Croscarmellose Sodium) market, with the United States accounting for approximately <strong>60% of regional consumption</strong>. This leadership position stems from the region's robust pharmaceutical manufacturing sector, stringent FDA regulations for excipient quality, and high adoption in tablet disintegration applications. The market benefits from strong R&amp;D investment in novel drug delivery systems, with croscarmellose sodium being a preferred superdisintegrant in <strong>over 70% of oral solid dosage formulations</strong> in the U.S. as of 2024.
    
  
  
  
    
      Regulatory excellence</p><p>
      The FDA's Current Good Manufacturing Practice (cGMP) standards ensure consistent quality in pharmaceutical excipients. Manufacturers in the region must comply with rigorous testing protocols for croscarmellose sodium, including particle size distribution and microbial limits, creating high barriers to entry but ensuring product reliability.
    
    
      Application diversity</p><p>
      While traditionally used in immediate-release tablets, North American manufacturers are increasingly adopting croscarmellose sodium for chewable tablets and orally disintegrating formulations. This expansion into novel applications is driving <strong>5-7% annual growth</strong> in consumption volumes.
    
    
      Supply chain dynamics</p><p>
      The region has developed a resilient supply network with localized manufacturing facilities from major players like DuPont and JRS Pharma. This regional production capability ensures stable pricing and availability despite global raw material fluctuations.
    
    
      Sustainability pressures</p><p>
      While performance remains the primary selection criterion, environmental concerns are prompting manufacturers to develop more sustainable production processes. This transition requires significant investment, potentially impacting profit margins in the short term.
    
  
</p><p>
</p><p><strong>Europe</strong></p><p>
Europe represents the second-largest market for croscarmellose sodium, characterized by strict compliance with European Pharmacopoeia standards and growing preference for plant-based excipients. The region shows particular strength in <strong>modified-release formulations</strong>, where controlled disintegration is critical. Germany and France lead in consumption, together accounting for <strong>45% of European demand</strong>. Recent EU regulations on pharmaceutical excipient traceability have increased documentation requirements, raising operational costs but improving supply chain transparency.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
The Asia-Pacific market is experiencing the fastest growth at <strong>8-10% CAGR</strong>, driven by expanding pharmaceutical production in India and China. While cost sensitivity remains a key market characteristic, quality standards are rapidly improving to meet export requirements. Local manufacturers are gaining market share through competitive pricing, though multinational brands still dominate the premium segment. The region's strong generic drug production fuels significant consumption in tablet formulations, particularly for copy products of discontinued branded medications.</p><p>
</p><p><strong>South America</strong></p><p>
South America's market is developing steadily, with Brazil representing <strong>over 60% of regional consumption</strong>. The market faces challenges including inconsistent regulatory enforcement and economic instability, which can disrupt supply chains. However, increasing local API production and growing pharmaceutical exports are creating new opportunities. The prevalence of tropical climates in the region has also spurred demand for moisture-resistant formulations where croscarmellose sodium's stability provides advantages.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
This emerging market shows potential, particularly in Gulf Cooperation Council (GCC) countries where pharmaceutical manufacturing is expanding. While current consumption volumes remain modest, government initiatives to develop local drug production capabilities are expected to drive <strong>6-8% annual growth</strong> through 2032. Africa presents opportunities in basic tablet formulations, though infrastructure limitations and fragmented distribution networks continue to challenge market development.</p><p><strong>Key Report Takeaways</strong></p><p>
</p><p>
</p><p>
</p><p>
</p><p>
</p><p>
</p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for Cross Linked Sodium Carboxymethyl Cellulose, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed Cross Linked Sodium Carboxymethyl Cellulose companies and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global Cross Linked Sodium Carboxymethyl Cellulose Market?</strong></p><p>
</p><p><strong>-&gt;</strong> Global Cross Linked Sodium Carboxymethyl Cellulose market was valued at <strong>USD 312.5 million in 2024</strong> and is expected to reach <strong>USD 482.7 million by 2032</strong>, growing at a <strong>CAGR of 6.4%</strong>.</p><p>
<strong>Which key companies operate in Global Cross Linked Sodium Carboxymethyl Cellulose Market?</strong></p><p>
</p><p><strong>-&gt; Key players</strong> include <strong>Prachin Chemical, Roquette, DuPont, Tianjin ILE Pharmaceutical Materials Co.,Ltd, and JRS Pharma</strong>, among others. These companies collectively held approximately <strong>65% market share</strong> in 2024.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p><strong>-&gt;</strong> Key growth drivers include <strong>increasing pharmaceutical production, rising demand for rapid-release drug formulations, and expansion of generic drug markets in emerging economies</strong>. The pharmaceutical segment accounts for <strong>78% of total consumption</strong>.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p><strong>-&gt; Asia-Pacific</strong> dominates the market with <strong>42% share</strong> in 2024, driven by pharmaceutical manufacturing growth in India and China. <strong>North America</strong> follows with <strong>28% market share</strong> due to stringent pharmaceutical regulations and advanced formulation technologies.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p><strong>-&gt;</strong> Emerging trends include <strong>development of low-viscosity grades for pediatric formulations, increasing adoption in food additives, and strategic collaborations between manufacturers and pharmaceutical companies</strong> to develop customized solutions.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/241245/global-cross-linked-sodium-carboxymethyl-cellulose-forecast-edition-market">
            https://www.24chemicalresearch.com/reports/241245/global-cross-linked-sodium-carboxymethyl-cellulose-forecast-edition-market</a></b></div><br>
            <b>Table of Content:</b><p>1 Introduction to Research & Analysis Reports<br />
    1.1 Cross Linked Sodium Carboxymethyl Cellulose Market Definition<br />
    1.2 Market Segments<br />
        1.2.1 Market by Type<br />
        1.2.2 Market by Application<br />
    1.3 Global Cross Linked Sodium Carboxymethyl Cellulose Market Overview<br />
    1.4 Features & Benefits of This Report<br />
    1.5 Methodology & Sources of Information<br />
        1.5.1 Research Methodology<br />
        1.5.2 Research Process<br />
        1.5.3 Base Year<br />
        1.5.4 Report Assumptions & Caveats<br />
2 Global Cross Linked Sodium Carboxymethyl Cellulose Overall Market Size<br />
    2.1 Global Cross Linked Sodium Carboxymethyl Cellulose Market Size: 2022 VS 2032<br />
    2.2 Global Cross Linked Sodium Carboxymethyl Cellulose Revenue, Prospects & Forecasts: 2018-2032<br />
    2.3 Global Cross Linked Sodium Carboxymethyl Cellulose Sales: 2018-2032<br />
3 Company Landscape<br />
    3.1 Top Cross Linked Sodium Carboxymethyl Cellulose Players in Global Market<br />
    3.2 Top Global Cross Linked Sodium Carboxymethyl Cellulose Companies Ranked by Revenue<br />
    3.3 Global Cross Linked Sodium Carboxymethyl Cellulose Revenue by Companies<br />
    3.4 Global Cross Linked Sodium Carboxymethyl Cellulose Sales by Companies<br />
    3.5 Global Cross Linked Sodium Carboxymethyl Cellulose Price by Manufacturer (2018-2023)<br />
    3.6 Top 3 and Top 5 Cross Linked Sodium Carboxymethyl Cellulose Companies in Global Market, by Revenue in 2022<br />
    3.7 Global Manufacturers Cross Linked Sodium Carboxymethyl Cellulose Product Ty</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/241245/global-cross-linked-sodium-carboxymethyl-cellulose-forecast-edition-market">
            https://www.24chemicalresearch.com/reports/241245/global-cross-linked-sodium-carboxymethyl-cellulose-forecast-edition-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>